Citigroup Inc Codiak Bio Sciences, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.32 - $0.9 $7 - $19	22 Added 5.15%	449 $0
Q3 2022 Nov 10, 2022	SELL	$0.82 - $3.19 $587 - $2,284	-716 Reduced 62.64%	427 $0
Q2 2022 Aug 10, 2022	SELL	$2.24 - $6.96 $60 - $187	-27 Reduced 2.31%	1,143 $3,000
Q1 2022 May 12, 2022	SELL	$4.3 - $12.95 $15,462 - $46,568	-3,596 Reduced 75.45%	1,170 $7,000
Q4 2021 Feb 10, 2022	BUY	$10.0 - $16.78 $29,510 - $49,517	2,951 Added 162.59%	4,766 $53,000
Q3 2021 Nov 10, 2021	BUY	$15.58 - $22.88 $28,277 - $41,527	1,815 New	1,815 $30,000

238K

Ticker CDAK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,995,200
Market Cap $360K
Description
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.